Impact of CYP2D6 genotype on fluoxetine exposure and treatment switch in adults and children/adolescents.

Eur J Clin Pharmacol · 2025 · PMC12511196 · PMID 40781498

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

However, a clear and highly significant difference in norfluoxetine-to-fluoxetine metabolic ratio consistent with genotype-predicted CYP2D6 activity suggests that CYP2D6 inhibition does not abolish an effect of genotype on fluoxetine metabolism.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.